ARDAT – Accelerating Research and Development for Advanced Therapies

April 26, 2022

ASPHALION is proud to be a partner in the ARDAT consortium, led by Pfizer and the University of Sheffield, and supported by Europe’s Innovative Medicines Initiative (IMI), which is jointly funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The ARDAT consortium aims to help standardise and accelerate development of ATMPs, allowing potentially transformative treatments to reach patients sooner.

As part of its ongoing work in the ARDAT consortium, ASPHALION has contributed to a Regulatory Perspective published in the April 2022 issue of “Cell and Gene Therapy Insights”, which summarises the current global regulatory landscape for biodistribution and shedding assessment of rAAV-based gene therapies and provides recommendations on future directions

The article includes a summary of current regulatory expectations for biodistribution and shedding, and describes the ongoing work of the ARDAT consortium to construct a database for the collation of biodistribution and shedding data and its use to inform recommendations for data standards and minimum requirements for reporting and publishing biodistribution and shedding studies.

You can read here the complete article, with the collaboration of Asphalion experts Chris Mann and Jon Giblin.

In case you need further information, you can also contact us.


Search News & Events

  • Filter by category


Related news and events

In2Sight | 4th annual meeting 3RS congress

At ASPHALION, we are part of the IN2SIGHT consortium, an EU-funded project, and we are delighted to be currently participating in the 4th annual meeting

Course | Regulatory aspects of vaccine development

TRANSVAC2 supported innovation for both prophylactic and therapeutic vaccine development by providing high-quality technical services across four different service platforms: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials. TRANSVAC also offered training courses to provide fundamental and advanced knowledge on a wide-range of vaccine development-related topics.


A lot of things have happened during these past three months. We received an award from AEFI as most engaged Company with its employees’ traning;

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting